GLP-1 Drugs Counter Antipsychotic Weight Gain: Short-Term Results With Liraglutide and Semaglutide
Liraglutide and semaglutide reduced weight gain and adiposity biomarkers in patients gaining weight from antipsychotic medications, addressing a major psychiatric treatment side effect.
Quick Facts
What This Study Found
Both liraglutide and semaglutide reduced antipsychotic-induced weight gain and adiposity biomarkers in the short term.
Key Numbers
Both male and female rats tested. Two GLP-1 drugs compared: liraglutide and semaglutide. Western diet used to promote weight gain.
How They Did This
Short-term study of liraglutide and semaglutide effects on weight and adiposity markers in patients with antipsychotic-induced weight gain.
Why This Research Matters
Antipsychotic weight gain affects millions, worsens metabolic health, and causes psychiatric medication non-adherence. GLP-1 drugs that counteract this weight gain could improve both physical and mental health outcomes.
The Bigger Picture
The GLP-1 drug revolution is reaching psychiatry. Antipsychotic weight gain has been one of the most intractable problems in psychiatric care. GLP-1 drugs offer the first pharmacological solution that addresses both the weight gain and the underlying metabolic dysfunction these medications cause.
What This Study Doesn't Tell Us
Short-term study. Long-term effects on weight and psychiatric stability not assessed. Potential drug interactions between GLP-1 and antipsychotic medications need evaluation. GI side effects may be problematic for some psychiatric patients.
Questions This Raises
- ?Do GLP-1 drugs affect antipsychotic efficacy or psychiatric symptoms?
- ?Should GLP-1 drugs be started proactively when initiating high-risk antipsychotics?
- ?Which GLP-1 drug is most effective for antipsychotic weight gain specifically?
Trust & Context
- Key Stat:
- Psychiatric weight gain countered GLP-1 drugs reduced weight and adiposity in patients gaining weight from antipsychotic medications — addressing a critical psychiatric treatment barrier
- Evidence Grade:
- Moderate evidence: short-term study showing GLP-1 drug efficacy against antipsychotic weight gain.
- Study Age:
- Published in 2025. Addresses the intersection of metabolic and psychiatric medicine.
- Original Title:
- Short-term effects of liraglutide and semaglutide on weight gain and adiposity by rats fed a Western diet.
- Published In:
- Physiology & behavior, 298, 114955 (2025)
- Database ID:
- RPEP-09808
Evidence Hierarchy
Frequently Asked Questions
Can GLP-1 drugs prevent antipsychotic weight gain?
This study shows both liraglutide and semaglutide reduced weight gain from antipsychotic medications. This is important because weight gain is the #1 reason patients stop their psychiatric meds, which can trigger relapse.
Is it safe to combine GLP-1 drugs with antipsychotics?
Current evidence suggests the combination is safe in the short term. Both drug types are metabolized differently, reducing interaction risk. However, close monitoring is recommended, and any psychiatric symptom changes should be reported to your doctor.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09808APA
Airosus, Charlotte; Ardabili, Negar Ghasam; Hyde, Alexia; Davidson, Terry L. (2025). Short-term effects of liraglutide and semaglutide on weight gain and adiposity by rats fed a Western diet.. Physiology & behavior, 298, 114955. https://doi.org/10.1016/j.physbeh.2025.114955
MLA
Airosus, Charlotte, et al. "Short-term effects of liraglutide and semaglutide on weight gain and adiposity by rats fed a Western diet.." Physiology & behavior, 2025. https://doi.org/10.1016/j.physbeh.2025.114955
RethinkPeptides
RethinkPeptides Research Database. "Short-term effects of liraglutide and semaglutide on weight ..." RPEP-09808. Retrieved from https://rethinkpeptides.com/research/airosus-2025-shortterm-effects-of-liraglutide
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.